Belite Bio announced positive secondary endpoint data from its Phase 3 DRAGON trial for tinlarebant in Stargardt disease, showing a marked divergence in quantitative autofluorescence between treatment groups. This data, combined with the previously met primary endpoint, strengthens the case for tinlarebant's efficacy and supports the recently completed New Drug Application to the FDA.
Belite Bio has reported additional positive secondary endpoint data for its lead therapeutic candidate, tinlarebant, in treating Stargardt disease. The key finding is that quantitative autofluorescence (qAF), a marker for toxic bisretinoid accumulation, remained stable or slightly decreased in treated subjects while increasing significantly in placebo subjects. This reinforces the previously announced primary endpoint success (35.7% reduction in lesion growth) and provides further evidence of tinlarebant's clinical efficacy. This news is a significant positive catalyst for Belite Bio, as it strengthens their New Drug Application (NDA) to the FDA, increasing the likelihood of approval. For traders, this presents a short-term opportunity for upward price movement in BLTE, with long-term implications tied to the eventual FDA decision and market adoption.